PFE Pfizer Inc.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
PFE stock data
()
Calendar
6 Aug 20
29 Oct 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Pfizer earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 15 Oct 20 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 36.55 | 13 | 475.15 | 78,638 |
| 15 Oct 20 | John D Young | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 36.55 | 12 | 438.6 | 47,342 |
| 15 Oct 20 | Rady A Johnson | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 36.55 | 4 | 146.2 | 5,664 |
| 15 Oct 20 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 36.55 | 32 | 1.17K | 10,668 |
| 12 Oct 20 | John D Young | Phantom Stock Units SSP Common Stock | Grant | Aquire A | No | 36.82 | 40 | 1.47K | 47,328 |
Institutional ownership Q2 2020
69.6% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2368 |
| Opened positions | 148 |
| Closed positions | 154 |
| Increased positions | 1026 |
| Reduced positions | 959 |
13F shares |
Current |
|---|---|
| Total value | 1.44T |
| Total shares | 3.87B |
| Total puts | 37.8M |
| Total calls | 24.21M |
| Total put/call ratio | 1.6 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 456.89M | $14.94B |
| BLK BlackRock | 427.53M | $13.98B |
| STT State Street | 298.9M | $9.77B |
| Wellington Management | 250.85M | $8.2B |
| Capital World Investors | 244.44M | $7.99B |
| Geode Capital Management | 89.14M | $2.91B |
| BAC Bank of America | 78.41M | $2.56B |
| NTRS Northern Trust | 68.73M | $2.25B |
| BK Bank of New York Mellon | 57.11M | $1.87B |
| State Farm Mutual Automobile Insurance | 56.54M | $1.85B |
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
AAH, adapted, addressing, Adjuvant, Agent, Albert, automatically, besylate, blinded, Bourla, BRIGHT, broadly, chose, cohort, Cortexyme, cyber, daunorubicin, deeply, Diflucan, dispense, dispensed, dispensing, ehf, England, epidemiological, faith, febrile, fewer, futility, glycoprotein, GmbH, good, gradual, gradually, guarantor, heard, hearing, inconsistent, insulin, intermediary, journal, lifesaving, Lightspeed, loan, London, malware, manifested, maternal, meningococcal, mentioned, messenger, Mexico, misrepresented, mobility, myelosuppressive, Neisseria, Neratinib, neuropathic, neutralizing, neutropenia, NHS, notice, Nyvepria, partnership, peer, phishing, precedent, preclinical, pregabalin, proven, PTC, Puma, RAR, ready, Reddy, regimen, RET, RNA, RSV, safe, sampling, schedule, Scotland, Scottish, SE, Shanghai, shorter, skin, spike, statutory, steady, syncytial, Trump, UK, unconditionally, unnecessary, vitro, withdrawn, young, Zoloft
Removed:
acute, aged, alectinib, ALK, Amneal, amyloid, artificially, Authorisation, autonomy, Avastin, Avillion, azacitidine, Baxter, begin, Ben, bevacizumab, Biotech, capture, cardiovascular, catch, category, Celltrion, ceritinib, cervical, CMA, comprised, consistently, crizotinib, culture, declared, Eurohealth, familial, fine, Genentech, germline, Gland, glioblastoma, Hengrui, Hikma, HR, induction, informed, Janssen, Jiangsu, Kabi, leaving, letter, Lorviqua, media, meglumine, modest, monotherapy, myeloid, NDA, neck, negotiating, Orion, OTC, output, overturned, persistent, pertaining, phenytoin, PLC, polyneuropathy, Precedex, premix, recurrent, retain, saline, Sarl, setting, sodium, solution, spinoff, split, susceptibility, TKI, Tribunal, unresectable, vaccinated, Venue, voluntarily, write, Zirabev
Financial reports
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
Current reports
8-K
Pfizer Reports Third-quarter 2020 Results
27 Oct 20
8-K
Regulation FD Disclosure
6 Aug 20
8-K
Pfizer Reports Second-quarter 2020 Results
28 Jul 20
8-K
Other Events
26 Jun 20
8-K
Entry into a Material Definitive Agreement
1 Jun 20
8-K
Other Events
28 May 20
8-K
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
22 May 20
8-K
Pfizer Prices $4,000,000,000 Debt Offering
19 May 20
8-K
Pfizer Reports First-quarter 2020 Results
28 Apr 20
8-K
Submission of Matters to a Vote of Security Holders
24 Apr 20
Registration and prospectus
425
Business combination disclosure
26 Jun 20
425
Business combination disclosure
18 Jun 20
425
Business combination disclosure
1 Jun 20
424B5
Prospectus supplement for primary offering
20 May 20
FWP
Free writing prospectus
19 May 20
424B3
Prospectus supplement
18 May 20
425
Business combination disclosure
30 Apr 20
424B5
Prospectus supplement for primary offering
26 Mar 20
425
Business combination disclosure
26 Mar 20
FWP
Free writing prospectus
25 Mar 20
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 20
PX14A6G
Letter to shareholders
6 Apr 20
PX14A6G
Letter to shareholders
3 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Mar 20
DEF 14A
Definitive proxy
13 Mar 20
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
Other
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17
NO ACT
No action letter
26 Jan 17
NO ACT
No action letter
10 Jan 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
4
PFIZER / JOHN D YOUNG ownership change
16 Oct 20
4
PFIZER / RADY A JOHNSON ownership change
16 Oct 20
4
PFIZER / JENNIFER B. DAMICO ownership change
16 Oct 20
4
PFIZER / ALBERT BOURLA ownership change
16 Oct 20
4
PFIZER / JOHN D YOUNG ownership change
13 Oct 20
4
PFIZER / JENNIFER B. DAMICO ownership change
13 Oct 20
4
PFIZER / RADY A JOHNSON ownership change
13 Oct 20
4
PFIZER / ALBERT BOURLA ownership change
13 Oct 20
4
PFIZER / JOHN D YOUNG ownership change
1 Oct 20
4
PFIZER / JENNIFER B. DAMICO ownership change
1 Oct 20
Patents
APP
Utility
Sodium Chloride Solution for Drug Reconstitution or Dilution
29 Oct 20
The invention provides methods for preparing pharmaceutical formulations for injection such that upon injection the formulation does not cause erythrocyte agglutination, hemolysis, and/or cell shrinkage.
GRANT
Utility
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
27 Oct 20
Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
GRANT
Utility
Unknown
27 Oct 20
In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide.
GRANT
Utility
Bruton's tyrosine kinase inhibitors
27 Oct 20
Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
GRANT
Utility
Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof
27 Oct 20
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide.